MoneyWorks4Me

Guj. Themis Biosyn - Quaterly Results

26 May 2026 Evaluate
The Revenue for the quarter ended  March 2026 of Rs. 442.33 millions grew by 17.22 % from Rs. 377.36 millions.Net profit declined -9.22% to Rs. 108.91 millions from Rs. 119.97 millions.The company reported a good operating profit of 202.81 millions compared to 173.86 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 442.33 377.36 17.22 1658.23 1508.00 9.96 1658.23 1508.00 9.96
Other Income 9.21 13.48 -31.68 24.28 24.32 -0.16 24.28 24.32 -0.16
PBIDT 202.81 173.86 16.65 779.58 712.76 9.37 779.58 712.76 9.37
Interest 19.06 0.71 2584.51 29.49 3.64 710.16 29.49 3.64 710.16
PBDT 183.75 173.15 6.12 750.09 709.12 5.78 750.09 709.12 5.78
Depreciation 40.38 12.28 228.83 129.19 53.75 140.35 129.19 53.75 140.35
PBT 143.37 160.87 -10.88 620.90 655.37 -5.26 620.90 655.37 -5.26
TAX 34.46 40.90 -15.75 154.08 167.66 -8.10 154.08 167.66 -8.10
Deferred Tax 10.70 2.32 361.21 46.22 2.80 1550.71 46.22 2.80 1550.71
PAT 108.91 119.97 -9.22 466.82 487.71 -4.28 466.82 487.71 -4.28
Equity 108.97 108.97 0.00 108.97 108.97 0.00 108.97 108.97 0.00
PBIDTM(%) 45.85 46.07 -0.48 47.01 47.27 -0.53 47.01 47.27 -0.53
Peers
Company Name CMP
Sun Pharma. Inds. 1866.00
Dr. Reddys Labs. 1172.05
Cipla 1372.25
Lupin 2092.00
Zydus Lifesciences 1137.35
View more..